Medication Options for ADHD in Adults: What You Can Get Through Telehealth

Attention-deficit/hyperactivity disorder does not end in childhood. An estimated 4.4 percent of adults in the United States live with ADHD, and many are never diagnosed until their twenties, thirties, or even later. If you have been struggling with chronic disorganization, difficulty focusing at work, impulsive decision-making, or a persistent sense that you are not reaching your potential, you may be wondering whether medication could help and whether you can access it through a telehealth visit.

The answer is nuanced. Some ADHD medications can be started through telehealth, while others require an in-person evaluation with a specialist. This guide will walk you through the options available to you, explain how non-stimulant medications work, clarify why stimulants have additional prescribing requirements, and describe the referral pathways that can connect you with the right provider for your needs.

Understanding ADHD in Adults

Adult ADHD is a neurodevelopmental condition characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with daily functioning. Unlike the stereotypical image of a hyperactive child bouncing off the walls, adult ADHD often presents more subtly. You may find yourself constantly losing track of tasks, struggling to meet deadlines, interrupting conversations without meaning to, or feeling an internal restlessness that makes it hard to relax.

The three primary presentations of ADHD are predominantly inattentive, predominantly hyperactive-impulsive, and combined type. Many adults, particularly women, are diagnosed later in life because their symptoms were overlooked during childhood. Inattentive presentations can be mistaken for laziness or lack of motivation, and hyperactive symptoms may manifest as internal restlessness rather than outward physical activity.

Diagnosis typically involves a thorough clinical interview, review of symptom history dating back to childhood, validated screening tools such as the Adult ADHD Self-Report Scale (ASRS-v1.1), and evaluation for coexisting conditions like anxiety, depression, or sleep disorders that can mimic or worsen ADHD symptoms.

Non-Stimulant Medication Options

Non-stimulant medications represent an important treatment pathway for adults with ADHD, especially when accessed through telehealth. Because these medications do not carry the same abuse potential or DEA scheduling restrictions as stimulants, they can be prescribed during a virtual visit after a thorough evaluation.

Atomoxetine (Strattera)

Atomoxetine is the only non-stimulant medication that is FDA-approved specifically for ADHD in adults. It works as a selective norepinephrine reuptake inhibitor, meaning it increases the availability of norepinephrine in the prefrontal cortex, the brain region most associated with attention, planning, and executive function.

Unlike stimulants that work within an hour of taking them, atomoxetine takes about four to six weeks to reach its full therapeutic effect. It is taken once or twice daily, and the dose is typically titrated upward gradually. Starting doses usually begin at 40 milligrams per day, with a target dose based on body weight, often reaching 80 to 100 milligrams daily.

Common side effects include decreased appetite, dry mouth, nausea, insomnia or drowsiness, and mild increases in heart rate or blood pressure. Most side effects are temporary and improve within the first few weeks of treatment. Atomoxetine carries a black box warning regarding suicidal ideation in children and adolescents, though this risk is lower in adults.

Atomoxetine is a particularly good choice for adults who have a history of substance use disorder, who experience significant anxiety alongside their ADHD, or who have cardiovascular concerns that make stimulant use inadvisable.

Bupropion (Wellbutrin)

Bupropion is an aminoketone antidepressant that acts on both dopamine and norepinephrine pathways. While it is FDA-approved for major depressive disorder and smoking cessation, it is widely used off-label for ADHD. Multiple clinical trials have demonstrated its efficacy in reducing ADHD symptoms, particularly in adults who also experience depression.

The extended-release formulation (Wellbutrin XL) is most commonly used, typically dosed at 150 to 450 milligrams per day. Like atomoxetine, bupropion takes several weeks to reach full effect and requires consistent daily dosing.

Side effects may include insomnia, dry mouth, headache, and decreased appetite. Bupropion lowers the seizure threshold, so it is contraindicated in patients with a seizure history or eating disorders such as bulimia or anorexia nervosa. It should not be combined with monoamine oxidase inhibitors.

The dual benefit of bupropion for both ADHD and depression makes it an attractive option for the many adults who struggle with both conditions simultaneously.

Other Non-Stimulant Options

Additional non-stimulant medications that may be considered include guanfacine extended-release (Intuniv) and clonidine extended-release (Kapvay). These alpha-2 adrenergic agonists are FDA-approved for ADHD in children and adolescents and are sometimes used off-label in adults, particularly when hyperactivity, impulsivity, or emotional dysregulation are prominent features. They work by modulating prefrontal cortex activity and can be especially helpful as adjunctive therapy.

Why Stimulant Medications Require Special Consideration

Stimulant medications, including amphetamine-based drugs like Adderall and lisdexamfetamine (Vyvanse) and methylphenidate-based drugs like Ritalin and Concerta, are considered the first-line treatment for ADHD. They have the strongest evidence base, work quickly, and are effective in about 70 to 80 percent of patients.

However, stimulants are classified as Schedule II controlled substances by the Drug Enforcement Administration. This classification reflects their potential for misuse and dependence. As a result, prescribing stimulants carries additional regulatory requirements and clinical responsibilities.

Federal regulations that were updated following the COVID-19 public health emergency have placed renewed emphasis on in-person evaluation for initial stimulant prescriptions. Many states now require an established patient-provider relationship that includes at least one in-person visit before a stimulant can be prescribed for the first time. Also, comprehensive ADHD evaluation for stimulant prescribing often requires detailed neuropsychological testing, review of educational and employment records, and screening for conditions like cardiac abnormalities or substance use history that necessitate a hands-on clinical assessment.

This is not a limitation of telehealth as a modality. Rather, it reflects the clinical and regulatory standard of care for prescribing high-risk controlled substances responsibly.

Referral Pathways for Stimulant Medications

If non-stimulant medications are not sufficiently managing your ADHD symptoms, or if your clinical picture suggests that stimulant therapy may be the best first-line approach, your telehealth provider can facilitate a referral to an appropriate specialist.

Frequently Asked Questions